The new code, J9295, is defined as "injection, necitumumab, 1 mg." This code is effective January 1, 2017.
Portrazza was approved by the US Food and Drug Administration on November 24, 2015. Portrazza is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC). Portrazza is not indicated for the treatment of nonsquamous NSCLC.

WARNING: CARDIOPULMONARY ARREST and HYPOMAGNESEMIA

Please see link for Important Safety Information, including Boxed Warnings for cardiopulmonary arrest and hypomagnesemia, and full Prescribing Information.